PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
981476225	rs4148740	PMID:18215618	ABCB1	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	yes	= 0.0029	260		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1446901561	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:12012142	CYP2C19	CYP2C19 *2/*2 + *2/*3 are not associated with clearance of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	no	> 0.05	12		East Asian	Metabolism/PK	false	12 healthy men was given a single dose of amitriptyline and pharmacokinetic parameters were determined. The subjects were divided into PM (two no function alleles) and carriers of one or no no function allele. No difference was found for the oral clearance, half-life time, maximum plasma concentration and time to peak plasma concentration were found between the two groups.	amitriptyline
1183617161	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:12172336	CYP2C19	CYP2C19 *2/*3 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	= 0.025	50		East Asian	Metabolism/PK	false		amitriptyline
1448276439	rs2032583	PMID:26704739	ABCB1	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.	no	= 0.442	73		Unknown	Efficacy	false	Efficacy was measured as change in Hamilton Rating Scale for Depression (HAM-D-17). Patients were randomized to a high-dose arm and a normal-dose arm. Assessment made after 0, 7, 14, 21, and 28 days of treatment.	amitriptyline; citalopram; escitalopram; nortriptyline; paroxetine; Selective serotonin reuptake inhibitors; sertraline; trimipramine; venlafaxine
1183617418	CYP2D6*1; CYP2D6*4	PMCID:PMC2291379	CYP2D6	CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	yes	= 0.01	807		European	Toxicity	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.)  Tricyclic antidepressants were grouped together for this analysis (45.9 % of patients were taking Amitriptyline; 8.2% Maprotiline;6.6% Clomipramine; 2.9% Nortriptyline;2.4% Imipramine;0.7% Dosulepin;0.3% Doxepin;0.2% Opipramol.  Counted as having ADRs if switched to a different antidepressant within the first 45 days.  Heterozygous patients did not have an increased risk of switching.  Genotypes were not in Hardy-Weinberg equilibrium; frequency below is for a larger population that included patients treated with other antidepressants.	amitriptyline; clomipramine; doxepin; imipramine; maprotiline; nortriptyline; opipramol
1451155705	CYP2D6 poor metabolizer phenotype	PMID:16129989	CYP2D6	CYP2D6 poor metabolizer phenotype is not associated with likelihood of adverse events due to amitriptyline or tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.	no		63		Unknown	Toxicity	false	Patients were phenotyped using dextromethorphan.	amitriptyline; tramadol
1450664831	CYP2C19*1; CYP2C19*2	PMID:15205367	CYP2C19	CYP2C19 *1/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	= 0.033	48		European	Metabolism/PK	false	Association foe increased plasma concentration.	amitriptyline
1446903476	CYP2D6*4	PMCID:PMC2291274	CYP2D6	CYP2D6 *4/*4 (assigned as poor metabolizers phenotype) is not associated with dose of amitriptyline as compared to CYP2D6 normal metabolizers.	no		23		European	Dosage	false	The study reports on CYP2D6PM (5) compared to EM (18, only phenotypically characterized) but diplotype was only reported for PM. 5 PMs (genotype as *4/*4) were included in the study.	amitriptyline
827808349	rs4244285	PMID:16044105	CYP2C19	Genotype AA is associated with increased log metabolic ratio of amitriptyline/nortriptyline when treated with amitriptyline as compared to genotype GG.	yes	= 0.004	69		Unknown	Metabolism/PK,Other	false	CYP2C19*2*2 had highest log(AT/NT), *1*2 had intermediate and *1*1 lowest.	amitriptyline
981476235	rs10280101	PMID:18215618	ABCB1	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	yes	= 0.0053	257		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1446903345	CYP2D6*1; CYP2D6*2; CYP2D6*4; CYP2D6*5; CYP2D6*9; CYP2D6*10	PMID:16024198	CYP2D6	CYP2D6 *4/*5 + *4/*4 are associated with decreased metabolism of amitriptyline as compared to CYP2D6 *9 + *10 + *1 + *2.	yes	= 0.002	195		European	Metabolism/PK	false	Postmortem toxicology cases. *3-*6 were grouped as non-functional. *1,*1XN,*2,*2XN,*9,*10 were grouped as functional. The association was found for MR AT/OH-AT and NT/OH-NT for carrier of no functional alleles. No diplotypes reported, *3, *4, *5, and *6 found in study. Metabolic ratio decreases from 0 to 1 to 2 functional alleles. No levels for amitriptyline and nortriptyline reported. Cases were drug poisoning intentional or accidental. No association was found between CYP2D6 PM status and accidental amitriptyline poisoning.	amitriptyline
827777223	rs2032582	PMID:16638956	ABCB1	Genotypes AA + AT are not associated with increased risk of side effects when treated with amitriptyline in people with Depression as compared to genotype CC.	no	= 0.026	50		European	Toxicity	false	When analyzing by specific side effects an association was seen for anticholinergic or gastrointestinal symptoms but this did not survive multiple testing adjustment.	amitriptyline
1183617183	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:12172336	CYP2C19	CYP2C19 *1/*3 + *2/*3 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	= 0.001	50		East Asian	Metabolism/PK	false	AT/NT ration is inversely related to desmethylation capacity.	amitriptyline
981476245	rs7787082	PMID:18215618	ABCB1	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.	yes	= 0.0046	257		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1446903849	CYP2D6*1; CYP2D6*4	PMCID:PMC2291379	CYP2D6	CYP2D6 *4/*4 is not associated with discontinuation of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline and opipramol in people with Depression as compared to CYP2D6 *1/*1.	no	= 0.15	807		European	Toxicity	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.) Tricyclic antidepressants were grouped together for this analysis (45.9 % of patients were taking Amitriptyline; 8.2% Maprotiline;6.6% Clomipramine; 2.9% Nortriptyline;2.4% Imipramine;0.7% Dosulepin;0.3% Doxepin;0.2% Opipramol.  No differences in discontinuation of antidepressants below 45 days was found.	amitriptyline; clomipramine; doxepin; imipramine; maprotiline; nortriptyline; opipramol
1451155689	CYP2D6 poor metabolizer phenotype	PMID:16129989	CYP2D6	CYP2D6 poor metabolizer phenotype is not associated with dose of amitriptyline or tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.	no		63		Unknown	Dosage	false	Patients were phenotyped using dextromethorphan.	amitriptyline; tramadol
1183615381	CYP2D6*1; CYP2D6*4	PMCID:PMC2291274	CYP2D6	CYP2D6 *4/*4 is associated with increased nortriptyline/(E)-10-OH-NT ratio when treated with amitriptyline as compared to CYP2D6 *1.	yes	= 0.0005	21		European	Metabolism/PK	false	The study reports on CYP2D6PM (4) compared to EM (17) but diplotype was only reported for PM. The comparison for the metabolite ratio is done in PM (carrying two non-functional alleles) versus subjects carrying one or two functional alleles (genotype not specified).	amitriptyline
1183617173	CYP2C19*1; CYP2C19*2	PMID:12172336	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	= 0.000004	50		East Asian	Metabolism/PK	false	AT/NT ration is inversely related to desmethylation capacity.	amitriptyline
655386253	rs2235015	PMID:18215618	ABCB1	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 0.025	339		European	Efficacy	false	Association was significant after correction for multiple testing at 6 weeks, but not so at 4 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1183617426	CYP2D6*1; CYP2D6*4	PMCID:PMC2291379	CYP2D6	CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.	yes	= 0.03	807		European	Dosage,Efficacy	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.) Tricyclic antidepressants were grouped together for this analysis (45.9 % of patients were taking Amitriptyline; 8.2% Maprotiline;6.6% Clomipramine; 2.9% Nortriptyline;2.4% Imipramine;0.7% Dosulepin;0.3% Doxepin;0.2% Opipramol.  Mean TCA dose was significantly lower at the 3rd and 4th prescription (difference 0.11 DDD). Genotypes were not in Hardy-Weinberg equilibrium; frequency below is for a larger population that included patients treated with other antidepressants.	amitriptyline; clomipramine; doxepin; imipramine; maprotiline; nortriptyline; opipramol
1451155681	CYP2D6 poor metabolizer phenotype	PMID:16129989	CYP2D6	CYP2D6 poor metabolizer phenotype is associated with decreased response to amitriptyline in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer phenotype.	yes	< 0.01	30		Unknown	Efficacy	false	Patients treated with amitriptyline had significantly greater pain intensity scores in the first week of treatment. However, this difference was not found at any other timepoint. Patients were phenotyped using dextromethorphan.	amitriptyline
1183615533	CYP2D6*4	PMCID:PMC3550197	CYP2D6	CYP2D6 *4/*4 is associated with toxicity when exposed to amitriptyline.	not stated		1		European	Toxicity	false	Intentionally overdosed on amitriptyline. Subject (found comatose) displayed prolonged rising of serum total amitriptyline concentrations for at least 6 days after admission.	amitriptyline
1183617453	CYP2C19*1; CYP2C19*2	PMID:15590749	CYP2C19	CYP2C19 *1/*1 is associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2C19 *1/*2 + *2/*2.	yes	= 0.00004	49		European	Toxicity	false	NOTE: Association only in patients carrying at least one non-functional CYP2D6 allele (*4,*5). Side effects were found to be associated with increased nortriptyline concentration. Study group patients carrying at least one non-functional allele (n=19) vs. patients carrying two functional alleles (n=30) with only *2 carriers were identified in study population. Side effects were measured with DOTES scale (analyses after 21 days of treatment, co-medication was allowed, AT dose was 150mg/day for most patients).	amitriptyline
1446903324	CYP2D6*4	PMCID:PMC3550197	CYP2D6	CYP2D6 *4/*4 is associated with increased concentrations of amitriptyline.	not stated		1		European	Metabolism/PK	false	Intentionally overdosed on amitriptyline. Subject (found comatose) displayed prolonged rising of serum total amitriptyline and nortriptyline concentrations for at least 6 days after admission.	amitriptyline
1183617193	CYP2D6*1; CYP2D6*2; CYP2D6*5; CYP2D6*10	PMID:12172336	CYP2D6	CYP2D6 *2/*5 + *1/*10 is not associated with differences in the ratio of nortriptyline and its metabolite when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	no	= 0.14	50		East Asian	Metabolism/PK	false	Study compared carry of two functional alleles (1/1; 1/2; 2/2) with carriers with only one functional allele (2/5; 1/10; 2/10).	amitriptyline
1183623082	CYP2D6*4	PMID:16024198	CYP2D6	CYP2D6 *4/*4 is associated with decreased clearance of amitriptyline in one suicide case.	not stated		1		European	Metabolism/PK,Toxicity	false	The highest femoral blood amitriptyline concentration in this study of postmortem toxicology cases was found in a CYP2D6 *4/*4 suicide case.	amitriptyline
1448612606	CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes	PMID:28350251	CYP2D6	CYP2D6 normal metabolizer and ultra-metabolizer genotypes is associated with decreased likelihood of Constipation, dry mouth, Fatigue, Urinary Retention and Vision Disorders when treated with amitriptyline in people with Diabetic Neuropathies as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.	not stated		31		Multiple groups, South Africa : 9 white, 21 black, 1 indian individuals	Toxicity	false	Authors considered this a pilot study and that 180 patients would be needed to properly evaluate significance.	amitriptyline
1183615397	CYP2D6*1; CYP2D6*4	PMCID:PMC2291274	CYP2D6	CYP2D6 *4/*4 is associated with increased amitriptyline/(E)-10- OH-AT ratio when treated with amitriptyline as compared to CYP2D6 *1.	yes	= 0.036	19		European	Metabolism/PK	false	The study reports on CYP2D6PM (3) compared to EM (16) but diplotype was only reported for PM. The comparison for the metabolite ratio is done in PM (carrying two non-functional alleles) versus subjects carrying one or two functional alleles (genotype not specified).	amitriptyline
981476266	rs4148739	PMID:18215618	ABCB1	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.	yes	= 0.0029	261		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1446903828	CYP2D6 poor metabolizers	PMID:22733128	CYP2D6	CYP2D6 poor metabolizers are not associated with discontinuation of amitriptyline or fluoxetine in people with Depressive Disorder, Major.	no		100		Unknown	Toxicity	false	Patients received either 20 mg/day fluoxetine or 75 mg/day amitriptyline. 4 UMs (more than two functional CYP2D6 alleles) discontinued treatment within the first 4 weeks, whereas no PM (no functional CYP2D6 allele) did so within 12 weeks. There were differences across CYP2D6 groups in the rate of ADP discontinuation at week 4 (P<0.01). The CYP2D6 activity value assigned to the reference allele *1 and *2 was 1, to *3, *4, *4xN, *5 and *6 was 0, to *10 or *17 was 0.5 and to multiplications of active alleles (*1xN or *2xN) was 2. Alleles or diplotypes found in study population or if patients received any co-medication were not reported.	amitriptyline; fluoxetine
655385916	rs2032583	PMID:18215618	ABCB1	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.	yes	= 0.0062	359		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks but not at 5 or at 6 weeks.	amitriptyline; citalopram; paroxetine; venlafaxine
1183617442	CYP2D6*1; CYP2D6*1xN; CYP2D6*2; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*41	PMID:15590749	CYP2D6	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	yes	= 0.00001	49		European	Toxicity	false	Study group patients carrying one non-functional allele  vs. patients carrying two functional alleles. No CYP2D6 PMs were identified. Side effects were measured with DOTES scale ( analyses after 21 days of treatment, co-medication was allowed, AT dose was 150mg/day for most patients). This group of patients had the highest risk of side effects regardless of 2C19*2 status.	amitriptyline
981476274	rs11983225	PMID:18215618	ABCB1	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.	yes	= 0.0034	257		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1446901519	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:12012142	CYP2C19	CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	yes	< 0.05	12		East Asian	Metabolism/PK	false	12 healthy men was given a single dose of amitriptyline and pharmacokinetic parameters were determined. The subjects were divided into PM (two no function alleles) and carriers of one or no no function allele. mean area under the plasma concentration time curve for PM (2207ng/ml/h) was significantly higher than for non-PM (1596ng/ml/h).	amitriptyline
1184467243	CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:8941025	CYP2D6	CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.	yes	< 0.05	74		Unknown	Toxicity	false	compared to random group of patients with depression. In the group of patients that experienced side effects the frequency (44%) of CYP2D6 *3, *4, *5, *6 carriage was higher than in a random group of patients with depression. This was more than twice the rate for the occurrence of mutant alleles in the other 56 psychiatric patients (21%) and in 80 random subjects from the general population (20%; p < 0.05).	amitriptyline; antidepressants; clomipramine; desipramine; fluoxetine; imipramine; nortriptyline; paroxetine; venlafaxine
1446901646	CYP2D6 poor metabolizers	PMID:3571939	CYP2D6	CYP2D6 poor metabolizers are associated with decreased metabolism of amitriptyline in people with Depression as compared to CYP2D6 normal metabolizers.	not stated		16		European	Metabolism/PK	false	Single patient observation, no statistic. 16 depressive patients were phenotype with debrisoquine as measure for CYP2D6 activity (MR >12.6 classified as PM). Patients received 150mg amitriptyline for 21 days. Two out of the 4 PM subjects had the highest plasma levels of amitriptyline and nortriptyline and the ratio of hydroxylated metabolites to the parent compounds appeared to be lower in these subjects compared to phenotypic EM. No information on possible co-medication of the depressive inpatients.	amitriptyline
981476405	rs3892097	PMCID:PMC2291379	CYP2D6	Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.	yes	= 0.01	807		European	Toxicity	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.)  Tricyclic antidepressants were grouped together for this analysis (45.9 % of patients were taking Amitriptyline; 8.2% Maprotiline;6.6% Clomipramine; 2.9% Nortriptyline;2.4% Imipramine;0.7% Dosulepin;0.3% Doxepin;0.2% Opipramol.  Counted as having ADRs if switched to a different antidepressant within the first 45 days.  Heterozygous patients did not have an increased risk of switching.  Genotypes were not in Hardy-Weinberg equilibrium; frequency below is for a larger population that included patients treated with other antidepressants.	amitriptyline; clomipramine; doxepin; imipramine; maprotiline; nortriptyline; opipramol
1183617206	CYP2D6*1; CYP2D6*2; CYP2D6*5; CYP2D6*10	PMID:12172336	CYP2D6	CYP2D6 *5/*10 + *10/*10 is associated with increased ratio of nortriptyline and its metabolite (NT/EHNT) when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.	no	= 0.068	50		East Asian	Metabolism/PK	false	Authors reported a trend of association. The study did not include poor metabilzers.	amitriptyline
1183684300	CYP2D6 poor metabolizers	PMID:1527229	CYP2D6	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.	yes	= 0.03	32		Unknown	Metabolism/PK	false	Patients were phenotyped with debrisoquine.	amitriptyline; clomipramine; doxepin; imipramine; trimipramine
981476290	rs10248420	PMID:18215618	ABCB1	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	yes	= 0.0095	256		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1446903928	CYP2C19*1; CYP2C19*2	PMID:15205367	CYP2C19	CYP2C19 *1/*2 + *2/*2 are not associated with concentrations of amitriptyline and nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	no	= 0.65	48		European	Metabolism/PK	false	Only *2 identified.	amitriptyline; nortriptyline
981476423	rs3892097	PMCID:PMC2291379	CYP2D6	Genotype TT is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.	yes	= 0.03	807		European	Dosage,Efficacy	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.) Tricyclic antidepressants were grouped together for this analysis (45.9 % of patients were taking Amitriptyline; 8.2% Maprotiline;6.6% Clomipramine; 2.9% Nortriptyline;2.4% Imipramine;0.7% Dosulepin;0.3% Doxepin;0.2% Opipramol.  Mean TCA dose was significantly lower at the 3rd and 4th prescription (difference 0.11 DDD). Genotypes were not in Hardy-Weinberg equilibrium; frequency below is for a larger population that included patients treated with other antidepressants.	amitriptyline; clomipramine; doxepin; imipramine; maprotiline; nortriptyline; opipramol
1446902772	CYP2D6*1; CYP2D6*1xN; CYP2D6*2; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*41	PMID:15590749	CYP2D6	CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are not associated with response to amitriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.	no	> 0.4	49		European	Efficacy	false	Study group patients carrying one non-functional allele vs. patients carrying two functional alleles. No CYP2D6 PMs were identified. Response was analyzed after 21 days of treatment, co-medication was allowed, AT dose was 150mg/day for most patients.	amitriptyline
981476298	rs2235040	PMID:18215618	ABCB1	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 6.6E-4	269		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
827777562	CYP2D6*1; CYP2D6*4	PMID:15205367	CYP2D6	CYP2D6 *4 is associated with increased plasma nortiptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	yes	< 1.0E-5	37		European	Metabolism/PK,Other	false		amitriptyline
1446903025	CYP2C19*1; CYP2C19*2	PMID:20531370	CYP2C19	CYP2C19 *2/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	< 0.05	150		Unknown	Metabolism/PK	false	Dutch patients from a psychiatric hospital generally genotyped for CYP2C19*2 and CYP2D6 *3, *4, *5,*6, and duplications were genotyped for CYP2C19*17. No information about treatment protocol.	amitriptyline
981476308	rs12720067	PMID:18215618	ABCB1	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 0.002	261		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1446903908	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMID:20531370	CYP2D6	CYP2D6 *3 + *4 + *5 + *6 are not associated with dose of amitriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1.	no	> 0.05	150		Unknown	Dosage	false	Dutch patients from a psychiatric hospital generally genotyped for CYP2C19*2 and CYP2D6 *3, *4, *5,*6, and duplications were genotyped for CYP2C19*17. Patients were treated with amitriptyline, but no information about treatment protocol.	amitriptyline
1183619031	CYP2D6*4	PMID:17008819	CYP2D6	CYP2D6 *4/*4 is associated with side effects when treated with amitriptyline.	not stated		1		European	Toxicity	false	Case report. Patients is CYP2D6*4/*4 and CYP2C19*2/*2 carrier. discontinued due to serious problems in balance when walking; patients also discontinued escitalopram regarding sedation, and paroxetine and sertraline without ADR reason. Patients was discharged on mirtazapine but further follow-up with patient was not possible.	amitriptyline
1446902626	CYP2C19*1; CYP2C19*2	PMID:16044105	CYP2C19	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	= 0.001	69		Unknown	Metabolism/PK	false	Patients from a psychiatric hospital were retrospective studied. Steady state serum concentration were used for calculation. Patients that were co-treated with medication that influences CYP2C19 were excluded. Only *2 was genotype. CYP2C19*2/*2 had highest log(AT/NT ratio), *1*2 had intermediate and *1*1 lowest. It seems CYP2D6 was also analyzed in association with log(AT/NT ratio) but no detailed data are presented except that conclusion that CYP2D6 did not affect the log(AT/NT ratio).	amitriptyline
1183623532	CYP2D6*1; CYP2D6*1xN; CYP2D6*2; CYP2D6*2xN	PMID:22733128	CYP2D6	CYP2D6 *1/*1xN + *2/*2xN are associated with increased likelihood of discontinuation when treated with amitriptyline or fluoxetine in people with Depressive Disorder, Major.	yes	< 0.01	100		Unknown	Toxicity	false	Patients received either 20 mg/day fluoxetine or 75 mg/day amitriptyline. 4 UMs (more than two functional CYP2D6 alleles) discontinued treatment within the first 4 weeks, whereas no PM (no functional CYP2D6 allele) did so within 12 weeks. There were differences across CYP2D6 groups in the rate of ADP discontinuation at week 4 (P<0.01). The CYP2D6 activity value assigned to the reference allele *1 and *2 was 1, to *3, *4, *4xN, *5 and *6 was 0, to *10 or *17 was 0.5 and to multiplications of active alleles (*1xN or *2xN) was 2. Alleles or diplotypes found in study population or if patients received any co-medication were not reported.	amitriptyline; fluoxetine
1448112308	CYP2D6*1; CYP2D6*2; CYP2D6*10; CYP2D6*87; CYP2D6*88; CYP2D6*89; CYP2D6*90; CYP2D6*91; CYP2D6*93; CYP2D6*94; CYP2D6*95; CYP2D6*97; CYP2D6*98	PMID:27097346	CYP2D6	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of amitriptyline as compared to CYP2D6 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	The variants were introduced into CYP2D6 cDNA and expressed in insect cells. The variants showed a decreased intrinsic clearance (Vmax/Km).Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.	amitriptyline
1183623913	CYP2D6*4	PMID:18359183	CYP2D6	CYP2D6 *4/*4 is associated with Poisoning when treated with amitriptyline and dextromethorphan.	no		1		Unknown	Toxicity	false	Case study. PM patient was treated with hydromorphone,  gabapentin, clonazepam, amitriptyline, paracetamol, and dextromethorphan leading to admission into an emergency department with profound coma. All drugs were stopped and patient recovered. In the hospital all drugs got re-initated under observation. Somnolence appeared on day three 30 hours after the first administration of dextromethorphan. Plasma drug concentration analysis showed relatively stable profiles for amitriptyline, nortriptyline, and hydromorphone but increasing concentrations for dextromethorphan.	amitriptyline; dextromethorphan
1446903003	CYP2C19*1; CYP2C19*2	PMID:20531370	CYP2C19	CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	< 0.05	150		Unknown	Metabolism/PK	false	Dutch patients from a psychiatric hospital generally genotyped for CYP2C19*2 and CYP2D6 *3, *4, *5,*6, and duplications were genotyped for CYP2C19*17. No information about treatment protocol. *2 was associated with higher MR of amitriptyline/nortriptyline. MR *2/*2=4.4 (significant from *1/*1), *1/*2=1.7 (significant from *2/*2), *2/*17=1.7, *1/*1=1.4	amitriptyline
1446903892	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:20531370	CYP2C19	CYP2C19 *17 + *2 are not associated with concentrations of amitriptyline and nortriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	no	> 0.05	150		Unknown	Metabolism/PK	false	Dutch patients from a psychiatric hospital generally genotyped for CYP2C19*2 and CYP2D6 *3, *4, *5,*6, and duplications were genotyped for CYP2C19*17. Patients were treated with amitriptyline, but no information about treatment protocol. CYP2C19 genotype is not associated with nortriptyline levels (or AT+NT levels or daily dose) if only 2C19 genotype was considered. In CYP2D6*1/*1 carriers the additional carriage of 2C19*17/*17 led to significant higher proportion of patients with nortriptyline serum levels above therapeutic range.	amitriptyline; nortriptyline
1446901072	CYP2D6 poor metabolizers	PMID:7159207	CYP2D6	CYP2D6 poor metabolizers are associated with decreased metabolism of amitriptyline in healthy individuals as compared to CYP2D6 normal metabolizers.	not stated		7		European	Metabolism/PK	false	Subjects were phenotyped with debrisoquine and bufuralol as measure for CYP2D6 activity. 3 Subjects qualified as PM based on bufuralol antimode (3.55) but only two based on the debrisoquine antimode (12.6). Phenotypic PMs had an absence of detectable amounts of hydroxy amitriptyline in blood and a marked reduction of HO-AT and hydroxy nortriptyline in urine (results in higher metabolic ratio for AT/HO-AT and NT/HO-NT) after a single dose. Based on the debrisoquine antimode one subject was a clear PM. This person showed decreased clearance of amitriptyline, a higher half-life time and higher AUC of amitriptyline and nortriptyline in blood.	amitriptyline
827777575	CYP2D6*1; CYP2D6*10	PMID:15205367	CYP2D6	CYP2D6 *10 is associated with increased plasma nortiptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	yes	< 0.001	28		European	Metabolism/PK,Other	false		amitriptyline
1183615357	CYP2D6*4	PMCID:PMC2291274	CYP2D6	CYP2D6 *4/*4 is associated with increased amitriptyline + nortriptyline plasma concentration in one CYP2D6 PM when treated with amitriptyline.	not stated		1		European	Metabolism/PK	false	The study reports on CYP2D6PM (5) compared to EM (18) but diplotype was only reported for PM. 5 PMs (genotype as *4/*4) were included in the study while in one PM the AT + NT plasma concentration (454 nM) exceeded the recommended plasma concentrations. no p-value reported	amitriptyline
1448276512	rs2235015	PMID:26704739	ABCB1	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.	no	= 0.513	73		Unknown	Efficacy	false	Efficacy was measured as change in Hamilton Rating Scale for Depression (HAM-D-17). Patients were randomized to a high-dose arm and a normal-dose arm. Assessment made after 0, 7, 14, 21, and 28 days of treatment.	amitriptyline; citalopram; escitalopram; nortriptyline; paroxetine; Selective serotonin reuptake inhibitors; sertraline; trimipramine; venlafaxine
827777570	CYP2D6*1; CYP2D6*41	PMID:15205367	CYP2D6	CYP2D6 *41 is associated with increased plasma nortriptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.	yes	< 1.0E-5	41		European	Metabolism/PK,Other	false		amitriptyline
981476212	rs2235067	PMID:18215618	ABCB1	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 0.0071	280		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1183623160	CYP2C19*1; CYP2C19*2	PMID:16024198	CYP2C19	CYP2C19 *2/*2 + *1/*2 is associated with decreased metabolism of amitriptyline in postmortem toxicology cases as compared to CYP2C19 *1/*1.	not stated	= 0.013	177		European	Metabolism/PK,Toxicity	false	Comparisons were done based on the number of functional CYP2C19 alleles (0,1 or 2 ) .   The correlation was with decreased demetnylation of amitryptiline.	amitriptyline
1183617529	CYP2C19*2	PMID:15168101	CYP2C19	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with increased plasma concentrations when treated with amitriptyline in people with Depressive Disorder, Major.	not stated		1		European	Metabolism/PK	false	Association with dose-corrected amitriptyline plasma concentration. Study investigated the effects of multiple antidepressants on side effects and response. In the text one PM patient on amitriptyline was mentioned with higher plasma level, therefore no p-value. Only *2 was genotype in study cohort.	amitriptyline
1448615842	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC5355968	CYP2C19	CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased exposure to amitriptyline in healthy individuals as compared to CYP2C19 *1/*1.	yes	= 0.0003	24		East Asian	Metabolism/PK	false		amitriptyline
1183617143	CYP2C19*1; CYP2C19*2	PMID:12172336	CYP2C19	CYP2C19 *2/*2 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	= 0.017	50		East Asian	Metabolism/PK	false		amitriptyline
1450664844	CYP2C19*1; CYP2C19*2	PMID:15205367	CYP2C19	CYP2C19 *1/*2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	yes	= 0.059	48		European	Metabolism/PK	false	Association is with decreased nortriptyline plasma concentration during amitriptyline treatment.	amitriptyline
1446903489	CYP2D6*4	PMCID:PMC2291274	CYP2D6	CYP2D6 *4/*4 is not associated with metabolism of amitriptyline as compared to CYP2D6 normal metabolizers.	no	= 0.066	21		European	Metabolism/PK	false	Parameter: amitriptyline + nortriptyline/ dose or AT/dose or NT/dose. The study reports on CYP2D6PM (5) compared to EM (18) but diplotype was only reported for PM. 5 PMs (genotype as *4/*4) were included in the study.	amitriptyline
1446902977	CYP2C19*1; CYP2C19*17	PMID:20531370	CYP2C19	CYP2C19 *17 is associated with increased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.	no	> 0.05	150		Unknown	Metabolism/PK	false	Dutch patients from a psychiatric hospital generally genotyped for CYP2C19*2 and CYP2D6 *3, *4, *5,*6, and duplications were genotyped for CYP2C19*17. No information about treatment protocol. Presence of *17 was associated with lower MR of amitriptyline/nortriptyline but not significant. In a subgroup of patients carrying 2C19*17 and CYP2D6*1/*1 the association was significant.	amitriptyline
1446903873	CYP2C19*1; CYP2C19*2	PMID:15590749	CYP2C19	CYP2C19 *1/*2 + *2/*2 are associated with increased concentrations of amitriptyline in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	yes	= 0.0197	49		European	Metabolism/PK	false	Study group patients carrying one or two non-functional allele vs. patients carrying two functional alleles. Mean serum concentration between dat 7 and 21 (co-medication was allowed, AT dose was 150mg/day for most patients).	amitriptyline